The collaborative care management (CCM) model has been demonstrated to be significantly more effective compared to usual care (UC) in depression management although an initial increase in cost measures was seen. In this paper, cost measures as well as clinical response were analyzed on patients with available follow-up data at six months. Records of 219 patients with follow-up data in CCM group and 119 in UC group were reviewed. At six months, there was a statistically significant clinical response rate among patients in CCM compared to UC group (P < 0.0001). Likewise, 65% in CCM group was "symptom-free" at 6 months vs. 31.9% in UC group (P < 0.0001). Among the responders in both groups, there was no statistical difference in cost measures. However, cost measures were significantly higher among non-responders compared to responders within CCM. Between the two models, the non-responders in UC had lower cost measures than the nonresponders under CCM.
The challenges with chronic disease management for mental health are consistent with other diseases such as diabetes in adults and asthma in children. In depression, a collaborative care model (CCM) involving the patient, primary care provider, psychiatry professionals, and care managers has shown to significantly improve therapeutic response to treatment and lower long-term health care costs, although short term costs have been increased. [1] [2] [3] [4] [5] Components of a CCM include a systematic screening approach, appropriate diagnostic screening and standardized monitoring of improvement to ensure adequate therapy, the development of a patient registry, the use of treatment guidelines, the introduction of a trained care manager, and a consultative relationship with psychiatry and the primary care provider.
Depression has been ranked ahead of coronary artery disease as the leading cause of disability and premature death worldwide. 6 However, usual care (UC) for the diagnosis and management of depression treats only 46% to 57% of patients, and only 18% to 25% receive adequate therapy. 7 The STAR*D trial, with aggressive management of depressed patients, suggests a theoretical possibility of 33% to 67% cumulative remission rates (defined as those symptom-free of depression) from the original cohort. [8] [9] [10] In 2007, the Institute for Clinical Systems Improvement (ICSI, www.icsi.org), along with 5 clinical sites across the state of Minnesota and 6 commercial health care plans, spearheaded the development of a CCM for depression treatment. This was intended to augment the relationship between the patient, the primary care provider (PCP), and the psychiatrist. The Patient Health Questionnaire-9 (PHQ-9), a widely validated and reliable instrument commonly used among primary care sites, was adopted by ICSI as the screening and monitoring tool for the program. 11 The CCM developed by ICSI allows for monthly payment to the clinical sites for the CCM services. Since implementation in 2008, 85 clinics statewide have begun offering CCM for depression.
To create change in health care delivery and improve quality of care to our patients, we need to assess the impact of new care models like CCM with respect to outcomes and to health care utilization. In previous studies, we have examined the cost impact and quality of improvement of depression management using a CCM of care. 12 The studies have been analyzed using an intention-to-treat model that includes all enrolled patients to determine effectiveness of care and costs compared with UC. A significant barrier to evaluation of chronic disease management is the lack of follow-up data, especially in UC.
Previous data have demonstrated that although CCM is significantly more effective than UC for improving depression management, there is a modest use of health care resources and cost increases for these patients in an intentto-treat analysis. 12, 13 However, we hypothesize that when we compare only those patients for whom we have followup data, UC and CCM may not have a significant cost differential. This article examines the impact on cost measures for 6 months after initial diagnosis of depression in patients who were treated with CCM compared with UC (and for whom we have follow-up data). The patients are stratified into categories of those who had clinical response, those in remission (symptom-free), and those who did not respond. The initial clinical characteristics of the nonresponding group are evaluated compared with those who are symptomfree of depression.
Methods
The study was performed at 3 clinical sites in Rochester, Minnesota, with a patient population of approximately 107 000. These patients are a community-based population and are approximately 50% community patients and 50% employees and dependents of Mayo Clinic. These primary care clinics are staffed with family medicine, primary care internal medicine and pediatric physicians and midlevel providers. Two of the clinical sites (clinics A and B) had the CCM process implemented in 2008. Clinic C implemented CCM later in 2010 and served as part of the control group as discussed below.
For the patients who met eligibility criteria and were offered CCM, the initial evaluation by the RN care manager included a screening tool for alcoholism (AUDIT 14 ), anxiety (GAD-7 15 ), and mood disorders (MDQ 16 ). The patient's prior psychiatric history and medications were reviewed. The CCM process involves weekly oversight by a psychiatrist, with medication or therapeutic changes managed by the primary care provider. Patient contact by the care manager is dictated by the clinical scenario and PHQ-9 testing; some patients are contacted weekly, some monthly.
Medical records of 684 patients were abstracted in a retrospective review for these cohorts. All patients were adults patients who received a clinical diagnosis of major depression or dysthymia (diagnosis codes: 296.2X, 296.3x, or 300.4) since March 2008, had a screening score of 10 or greater on the PHQ-9, and had given permission to have their medical records reviewed.
The patients were in 3 groups. The first group of 219 (32.0%) were enrolled in CCM treatment for depression. The second group included 120 (17.4%) patients who were offered care management but chose not to be enrolled in the program or left treatment early (UC1). The final group (UC2) was made up of patients from these 3 primary care clinics who were never enrolled in CCM (345 or 53.4%). Of these groups, data compliance for 6-month follow-up PHQ-9s was 200 of 219 (91.3%) for CCM, 57 of 120 (47.5%) for UC1, and 62 of 345 (18.0%) for UC2. The remaining statistics and discussion will focus only on the patients who had follow-up data at 6 months.
The dependent variables in this study were the CPT (Current Procedure Terminology published by the American Medical Association) costs for all of the patient's medical care for 6 months after diagnosis and the differential between the pre-and post-index date CPT costs for the 6 months before and after the index date. Because direct comparison of billing data could be biased, the standard national fees as listed by the Center for Medicare and Medicaid services (CMS) were used. CPT codes that were not listed in the CMS database were excluded. For example, the codes 99213 and 99214 are listed with the fees in Minnesota of $43.73 and $67.61, respectively. Because the total CPT costs measured had unequal statistical variances between the groups studied, rank measures were also compared. The lowest CPT costs were ranked as 1, the highest as 684. This allows another comparison of the data, limiting the potential for the impact of wide variations in actual costs.
The independent variables included age, gender, marital status, history of depression (within 2 years), initial PHQ-9 score, and the number of outpatient medical office visits in the 6 months prior to index visit for any reason.
Statistical analysis used chi-square testing for the categorical variables. Because the data were not in a normal distribution, Mann-Whitney testing was performed for numerical variables. Two trained medical secretaries were used as abstractors. All information was obtained from the patient's electronic medical record. The study was approved by the institutional review board.
Results
To improve the numbers for statistical analysis, the 2 usual care groups (UC1 and UC2) were examined and found to not have statistically significant differences in total CPT costs at 6 months (P = .91), in CPT cost rankings (P = .91), or in CPT cost differential (P = .28). For this reason, they were combined as a UC group of 119 patients for whom we have 6-month follow-up PHQ-9 data.
Of the patients with data at 6 months, the CCM group had a rate of clinical response of 80.5% (161/200) compared with the UC group of 52.9% (63/119) (P < .0001). Clinical response is defined as a decrease in the PHQ-9 score by 50% or more. Clinical remission is defined as a PHQ-9 score of less than 5 on 2 tests within 2 months. Because only one follow-up PHQ-9 was studied, we can only comment that these patients with a PHQ-9 less than 5 were "symptom-free." The CCM group was 65.0% (130/200) symptom-free at 6 months, compared with 31.9% (38/119) in the UC group (P < .0001) (Figure 1 ). Thirtynine patients in the CCM group were nonresponders as were 56 in the UC group.
For the patients who had PHQ-9 data at 6 months, there was no statistical difference between CCM versus UC groups in regard to age, gender, history of depression, marital status, number of clinical visits in the prior 6 months, or CPT costs for the 6 months prior to the index PHQ-9 (Table 1) .
When we examined the dependent variables, the CCM and UC groups were divided into those showing a clinical response, those who were symptom-free (a subset of those who responded), and those who were nonresponders. In the patients who had a clinical response or were symptom-free at 6 months, CCM and UC had statistically similar CPT costs, cost rankings, and CPT differentials. However, nonresponding patients in CCM (n = 39) had significantly increased 6-month CPT costs compared with the nonresponding patients in UC (n = 56) ($642.14 vs $504.44, P = .007). Costs ranks were also significantly elevated for the nonresponding patients of CCM versus UC (477.82 vs 361.02, P = .007). CPT cost differential takes into account the prior 6 months of utilization for each patient; this also was significantly more elevated in the CCM versus UC nonresponders ($365.84 vs $194.40, P = .003) ( Table 2) .
Within the CCM group, CPT costs for nonresponders were statistically higher compared with those who had responded to treatment ($642.14 vs $423.66, p= 0.001) and were symptom-free ($642.14 vs $399.73, P < .001) ( Table 3) . Cost ranks were also significantly elevated in the nonresponding group of CCM patients compared with those who responded (477.82 vs 363.07, P = .001) and those who were symptom-free (477.82 vs 351.27, P < .001). The CPT cost differential was similarly elevated in the CCM nonresponders versus CCM responders ($365.84 vs $234.96, P = .03) and those in CCM who were symptom-free ($365.84 vs $216.29, P = .007).
Although the costs structures were elevated, none of the baseline clinical or demographic data obtained in this study appeared to predict which CCM patient would be at increased risk to be in the nonresponding group. There was no statistically noted difference in age, initial PHQ-9, marital status, gender, history of depression, or prior use of clinic visits (Table 4 ).
Discussion
In this population of patients from whom we have data at 6-month follow-up, cost measures (CPT costs, cost ranks, and CPT differentials) show significant cost differentials between patients who responded to care compared with those who did not. Among those who received CCM, the Figure 1 . Comparison of patients who showed clinical response and those who were symptom-free of depression at 6 months between collaborative care management (CCM) and usual care (UC). nonresponsive patients had the highest expense. These nonresponders in the CCM group cost more than the nonresponders under UC. Among the patients whose depression improved in 6 months, there was no difference in cost measures between CCM and UC. The hypothesis of this study, that CCM and UC would have similar cost metrics in those patients who have data at 6 months, is supported for those patients who responded. However, the data suggest that CCM has increased cost metrics for those patients without a clinical response compared with UC. Two important groups were identified in this study. First, we found that among those patients with follow-up data who were in usual care, 31.9% were symptom-free at 6 months. These patients may differ from others in their willingness to provide follow-up information, but if distinguishing clinical and psychological characteristics of this group can be identified, no additional resources (collaborative care management) may be needed for their care, saving the extra care for those who need it.
A second interesting group was those patients who received CCM but did not respond at 6 months (39/200 in this sample). This group seems to be associated with most of the increased cost of CCM with little evidence of clinical improvement. Future studies should be directed at the clinical and psychological predictive factors for this group, allowing for earlier or alternative interventions, which it is hoped will improve clinical outcomes and limit health care utilization.
We did not observe any of the independent variables analyzed to significantly predict nonresponsiveness to CCM model. Looking into other variables such as number of medical comorbidities or presence of other psychiatric illnesses may yield new findings. This study may not be able to be generalized to other clinical sites. The patient population was not a significantly diverse population in terms of ethnicity, medical or psychiatric comorbidity, or access to health care insurance. Those patients who agreed to care management may be different in their willingness to change or clinical characteristics than those who were not referred or who refused care management. All subjects were adults, and their data cannot be generalized to a pediatric population. This study included practitioners in one community, and the findings may not necessarily be generalized to other sites or practitioners. Because the data were collected by billing information, charges from outside the institution were not captured.
Conclusions
The collaborative care management model for depression resulted in statistically significant higher clinical response and remission rates at 6 months compared with usual care. Cost measures were not statistically different among the responders in both groups, but among the nonresponders, cost was significantly higher among those in CCM. This study has defined 2 population groups for future evaluation. There is a subset of patients who can become symptom-free with UC and probably will not need significant changes in the management of depression. The other group includes those who have not responded at 6 months, even when engaged with a care manager. Future studies are needed to determine the clinical and psychological characteristics of these groups and work toward early identification and implementation of cost-effective changes. 
